Lupin launches drug to control postpartum hemorrhage after USFDA nod

Drug maker Lupin on Monday launched Methylergonovine Maleate tablets, used for prevention and control of postpartum hemorrhage, in the American market.

The company has launched the product in the US after having received approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a statement.

Lupin's product is the generic equivalent of Novartis Pharmaceuticals Corp's Methergine which is indicated for prevention and control of postpartum hemorrhage.

As per the latest industry estimates, Methylergonovine Maleate tablets had annual sales of around  $71.5 million in the US.

Lupin shares were trading 1.18 per cent up at Rs 772.10 on BSE.

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel